课题基金 / 基金详情

CHARACTERIZATION OF THE P21 RAS ONCOGENE PRODUCT

CHARACTERIZATION OF THE P21 RAS ONCOGENE PRODUCT
P21 RAS 癌基因产品的表征
批准号:
4692395
负责人:
S HATTORI
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
负责肿瘤发生的v-ras-H致癌基因已被证实
英文摘要
The v-ras-H oncogene, which is responsible for tumorigenesis, has been cloned into E. coli expression vector, and its gene product was purified in a large amount which is sufficient for biochemical and enzymological analyses. Purified protein showed full biochemical activities of GTP/GDP binding, autokinase and GTPase. In order to determine the active site of p21, the effects of antibodies against p21 and N-ethylmaleimide (NEM) were studied. Among six monoclonals, only Y13-259 inhibited p21 activities as much as 80%, which indicated that Y13-259 affected the active site. NEM inactivated p21 activities, indicating that cysteine residue is involved in the active site. The active site could also be specifically labeled by a photoaffinity analogue, P3-(4-azidoanilido)-5'GTP. It was found that monoclonal antibodies against p21 weakly cross-immunoprecipitated the G-protein of adenylate cyclase labeled by 32P-ADP-ribosylation, suggesting that either there might be weak interaction between p21 and G-protein or there might be structural homology between two proteins. New monoclonal antibodies were obtained after immunization of p21 expressed in E. coli into mice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金